Coronary Heart Disease

Cardiovascular
11
Pipeline Programs
21
Companies
20
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
2
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Peptide
150%
+ 25 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
ACARBOSEApproved
acarbose
Unknown Company
oral2011
Bayer
PRECOSEApproved
acarbose
Bayer
oral1995

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
AcarbosePhase 41 trial
Active Trials
NCT00829660Completed6,526Est. Apr 2017
Innogene Kalbiotech
Innogene KalbiotechSingapore - Singapore
1 program
1
Hypertonic sodium lactatePhase 41 trial
Active Trials
NCT01654653CompletedEst. Mar 2009
Bristol Myers Squibb
1 program
1
Updated CHD risk profilesPhase 41 trial
Active Trials
NCT00264394Completed4,097Est. Feb 2010
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
DalcetrapibPhase 32 trials
dalcetrapibPhase 21 trial
Active Trials
NCT00400439Completed77Est. Jan 2008
NCT01363999Completed24Est. Jul 2011
NCT00658515Completed15,871Est. Sep 2012
Pfizer
PfizerNEW YORK, NY
1 program
1
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg dailyPhase 31 trial
Active Trials
NCT00319566Completed2,430Est. Jul 2001
DS
Daiichi SankyoChina - Shanghai
1 program
1
Pactimibe, CS-505Phase 21 trial
Active Trials
NCT00185042Completed534Est. Jul 2005
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
AnfibatidePhase 1Peptide1 trial
Active Trials
NCT01588132Completed94Est. Mar 2011
CT
1 program
1
domestic polysaccharide superparamagnetic iron oxide nanoparticlePhase 11 trial
Active Trials
NCT05032937CompletedEst. Jan 2023
M&
Merck & Co.RAHWAY, NJ
3 programs
Case Management "CM CHD"N/A
Comprehensive non invasive cardiovascular examinationN/A
StatinN/ASmall Molecule1 trial
Active Trials
NCT00723723Completed555Est. Jun 2009
GS
Gilead SciencesFOSTER CITY, CA
2 programs
Comprehensive non invasive cardiovascular examinationN/A
Comprehensive non invasive cardiovascular examinationN/A
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
Comprehensive non invasive cardiovascular examinationN/A
Comprehensive non invasive cardiovascular examinationN/A
Abbott
AbbottABBOTT PARK, IL
2 programs
Comprehensive non invasive cardiovascular examinationN/A
Comprehensive non invasive cardiovascular examinationN/A1 trial
Active Trials
NCT01196273Completed1,424Est. Dec 2011
Providence Therapeutics
1 program
AIRWISEN/A1 trial
Active Trials
NCT06384625CompletedEst. Nov 2025
Biotronik
BiotronikGermany - Berlin
1 program
COMBON/A1 trial
Active Trials
NCT03216733Active Not Recruiting3,148Est. Dec 2028
OrbusNeich
OrbusNeichChina - Hong Kong
1 program
COMBON/A
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Case Management "CM CHD"N/A1 trial
Active Trials
NCT01725074Unknown320Est. Mar 2013
C
CordisFL - Miami Lakes
1 program
Economic Evaluation German Drug-Eluting Stent RegistryN/A1 trial
Active Trials
NCT00866398Completed3,973Est. Mar 2008
AM-Pharma
AM-PharmaNetherlands - Utrecht
1 program
Hamburg City Health Study - a German Cohort StudyN/A1 trial
Active Trials
NCT03934957RecruitingEst. Dec 2028
LB
Lepu BiopharmaChina - Shanghai
1 program
Single anti-platelet therapyN/A1 trial
Active Trials
NCT04995159Not Yet RecruitingEst. Jan 2028
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Twenty-year Follow-up of the Inter99 CohortN/A1 trial
Active Trials
NCT05166447Enrolling By Invitation4,000Est. Dec 2028
Takeda
TakedaTOKYO, Japan
1 program
Voglibose tabletsN/A1 trial
Active Trials
NCT00724542Unknown1,600Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BayerAcarbose
Innogene KalbiotechHypertonic sodium lactate
Bristol Myers SquibbUpdated CHD risk profiles
RocheDalcetrapib
PfizerPremarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Rochedalcetrapib
Daiichi SankyoPactimibe, CS-505
Chia Tai TianQing Pharmaceutical Groupdomestic polysaccharide superparamagnetic iron oxide nanoparticle
RocheDalcetrapib
Lee's PharmaceuticalAnfibatide
Providence TherapeuticsAIRWISE
Novo NordiskTwenty-year Follow-up of the Inter99 Cohort
Lepu BiopharmaSingle anti-platelet therapy
BiotronikCOMBO
AM-PharmaHamburg City Health Study - a German Cohort Study

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 44,673 patients across 20 trials

NCT00829660BayerAcarbose

Acarbose Cardiovascular Evaluation Trial

Start: Feb 2009Est. completion: Apr 20176,526 patients
Phase 4Completed
NCT01654653Innogene KalbiotechHypertonic sodium lactate

Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients

Start: Jul 2008Est. completion: Mar 2009
Phase 4Completed
NCT00264394Bristol Myers SquibbUpdated CHD risk profiles

Cardiovascular Risk Factor Management in HIV Infection

Start: Jul 2006Est. completion: Feb 20104,097 patients
Phase 4Completed
NCT00658515RocheDalcetrapib

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Start: Apr 2008Est. completion: Sep 201215,871 patients
Phase 3Completed
NCT00319566PfizerPremarin .625 mg daily plus medroxyprogesterone 2.5 mg daily

Heart and Estrogen-Progestin Replacement Study (HERS)

Start: Jul 1992Est. completion: Jul 20012,430 patients
Phase 3Completed
NCT00400439Rochedalcetrapib

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Start: Jan 2007Est. completion: Jan 200877 patients
Phase 2Completed
NCT00185042Daiichi SankyoPactimibe, CS-505

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Start: Nov 2002Est. completion: Jul 2005534 patients
Phase 2Completed
NCT05032937Chia Tai TianQing Pharmaceutical Groupdomestic polysaccharide superparamagnetic iron oxide nanoparticle

the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

Start: Oct 2021Est. completion: Jan 2023
Phase 1Completed
NCT01363999RocheDalcetrapib

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Start: Jun 2011Est. completion: Jul 201124 patients
Phase 1Completed
NCT01588132Lee's PharmaceuticalAnfibatide

Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

Start: Sep 2010Est. completion: Mar 201194 patients
Phase 1Completed
NCT06384625Providence TherapeuticsAIRWISE

Developing and Evaluating an Indoor Air Pollution Intervention Among Cardiovascular Patients: the AIRWISE Study

Start: Jul 2024Est. completion: Nov 2025
N/ACompleted
NCT05166447Novo NordiskTwenty-year Follow-up of the Inter99 Cohort

Twenty-year Follow-up of the Inter99 Cohort

Start: Sep 2021Est. completion: Dec 20284,000 patients
N/AEnrolling By Invitation
NCT04995159Lepu BiopharmaSingle anti-platelet therapy

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Start: Sep 2021Est. completion: Jan 2028
N/ANot Yet Recruiting
NCT03216733BiotronikCOMBO

SORT OUT X - Combo Stent Versus ORSIRO Stent

Start: Jun 2017Est. completion: Dec 20283,148 patients
N/AActive Not Recruiting
NCT03934957AM-PharmaHamburg City Health Study - a German Cohort Study

Hamburg City Health Study - a German Cohort Study

Start: Feb 2016Est. completion: Dec 2028
N/ARecruiting
NCT01725074Heidelberg PharmaCase Management "CM CHD"

Randomized Control Trial to Evaluate Effectiveness of a Case Managment Program Regarding Psychosocial Well-being and Disease Symptoms Health for Patients With Multimorbid Coronary Heart Disease (CHD) Patients (KHK ProMA)

Start: Jul 2011Est. completion: Mar 2013320 patients
N/AUnknown
NCT01196273AbbottComprehensive non invasive cardiovascular examination

Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up

Start: Dec 2009Est. completion: Dec 20111,424 patients
N/ACompleted
NCT00724542TakedaVoglibose tablets

Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.

Start: Jul 2008Est. completion: Dec 20101,600 patients
N/AUnknown
NCT00723723Merck & Co.Statin

Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

Start: Jan 2008Est. completion: Jun 2009555 patients
N/ACompleted
NCT00866398CordisEconomic Evaluation German Drug-Eluting Stent Registry

Economic Evaluation German Drug-Eluting Stent Registry

Start: Dec 2005Est. completion: Mar 20083,973 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 44,673 patients
21 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Aortic Valve Stenosis(27)Atherosclerosis(27)